Approved for use through 07/31/2006 (OMS 055
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMU.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

U.S. PATENTS

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)
(·,

Application Number		10758764
Filing Date		2004-01-16
First Named Inventor	Akira	Yamaguchi
Art Unit		1745
Examiner Name	Mark Ruthkosky	
Attornov Docket Numb	or	00702000 5774

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	)ate	Name of Pate of cited Docu	entee or Applicant ment	Relev		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Relev		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor			
				FOREIG	3N PA1	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>		Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	T
	1	09-035718	JP			1997-02-07	Toshiba Batlery Co	Ltd			×
	2	09-063648	JP			1997-03-07	Yuasa Corp				×
	3	09-092265	JP			1997-04-04	Denso Corp				×

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

11-154515

pplication Number		10758764
iling Date		2004-01-16
irst Named Inventor	Akira	Yamaguchi
rt Unit		1745
xaminer Name	Mark Ruthkosky	
ttomey Docket Numb	mbor 00702000 5774	

X

Denso Corp

	5	11-224670	JP		1999-08-17	Hitachi Ltd		×
	6	2001-155790	JP		2001-06-08	Sany Corp		×
	7	2002-298844	JP		2002-10-11	National Institute of Advanced Industrial & Tech.		×
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No No (book, negazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Ţ5

1999-06-08

A

E

JF

Japanese Office Action issued on January 30, 2007

EXAMINER SIGNATURE

Examiner Signature

Date Considered

Date Considered

Examiner Right in the Considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

See Kind Code of USPTO Petent Documents at swee USPTO\_GDV or MEPF 801.04. 2 Enter office that issued the document, by the Voletion Code (WIPO Standard ST.3). 3 For Japanese petent for counters, the isolation of the year of the register many precised the serial number of the petent format of the petent format period counters and only the proper than the petent of the petent format of t

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10758764
Filing Date		2004-01-16
First Named Inventor	Akira	Yamaguchi
Art Unit	1745	
Examiner Name	Mark Ruthkosky	
Attorney Docket Number		09792909-5771

#### CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3/(40.)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

\_ N--

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	Date (YYYY-MM-DD)	
Name/Print	Registration Number	

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Officer, U.S. perpartment of Commence, P. 0. Box 1445, Alexandria, V.3.2311-4450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.